Organon & Co. (NYSE:OGN) Issues Quarterly Earnings Results

Organon & Co. (NYSE:OGN) released its earnings results on Thursday. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09), Zacks reports. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. Organon & Co. updated its FY 2025 guidance to EPS.

Organon & Co. Stock Performance

OGN stock traded up $1.43 during trading on Thursday, reaching $16.13. The stock had a trading volume of 5,934,328 shares, compared to its average volume of 2,687,397. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The stock’s 50 day moving average is $15.33 and its two-hundred day moving average is $17.54. The firm has a market cap of $4.15 billion, a PE ratio of 3.20, a PEG ratio of 0.83 and a beta of 0.76. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10.

Wall Street Analysts Forecast Growth

Separately, TD Cowen raised Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $21.33.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.